Moreover, patients with metastatic CRC-bearing K-Ras mutations overexpress epidermal growth factor receptor (EGFR), a transcriptional target of the Wnt/β-catenin pathway, and are resistant to EGFR mAb drugs, such as cetuximab and panitumumab used as CRC chemotherapy [1,38,39] Thus, it is necessary to develop drugs that simultaneously target the Wnt/β-catenin and Ras/ERK pathways for effective CRC treatment. The gene discussed is KRAS; the disease is colorectal carcinoma.